Last reviewed · How we verify

NCT05130775

Measurement of Tricuspid Regurgitation Volume for Assessment of Tricuspid Regurgitation Using 3D Transesophageal Echocardiography

Withdrawn Last updated 5 January 2024
What this trial tests

trial testing Transesophageal echocardiograpgy in Tricuspid Regurgitation. Withdrawn.

Timeline
5 August 2022
Primary endpoint
5 August 2022
5 August 2022

Quick facts

Lead sponsorTufts Medical Center
StatusWithdrawn
Study typeOBSERVATIONAL
Start date5 August 2022
Primary completion5 August 2022
Estimated completion5 August 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Tufts Medical Center

Who can join

18 and older, any sex, with Tricuspid Regurgitation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a prospective observational chart review. The aim of the study is to evaluate tricuspid regurgitation volume using 3D volumetric assessment as an accurate method for tricuspid regurgitation severity in comparison to VCA.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Added value of 3D echocardiography in the diagnosis and prognostication of patients with right ventricular dysfunction.
    Randazzo M, Maffessanti F, Kotta A, Grapsa J, et al · · 2023 · cited 4× · PMID 38179507 · DOI 10.3389/fcvm.2023.1263864

Verify or expand the search:

Other recruiting trials for Tricuspid Regurgitation

Currently open trials in the same condition.

Other Tufts Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05130775.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing